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Abstract
Background: Positive findings from the phase III MPACT trial led to the regulatory approval of nab-paclitaxel plus 
gemcitabine as a treatment option for patients with metastatic pancreatic cancer. This report is an update of overall 
survival (OS) based on longer follow-up.
Methods: Patients (n = 861) with metastatic pancreatic cancer and a Karnofsky performance status of 70 or greater were 
randomly assigned one to one to receive nab-paclitaxel + gemcitabine or gemcitabine alone. Efficacy data for this post hoc 
analysis were collected through May 9, 2013. Exploratory analyses of carbohydrate antigen 19-9 (CA19-9) and neutrophil-
to-lymphocyte ratio (NLR) were conducted. The primary efficacy endpoint was OS, which was analyzed for all randomly 
assigned patients by the Kaplan-Meier method. All statistical tests were two-sided.
Results: The median OS was statistically significantly longer for nab-paclitaxel plus gemcitabine vs gemcitabine alone 
(8.7 vs 6.6 months, hazard ratio [HR] = 0.72, 95% confidence interval [CI] = 0.62 to 0.83, P < .001). Long-term (>three-year) 
survivors were identified in the nab-paclitaxel plus gemcitabine arm only (4%). In pooled treatment arm analyses, higher 
CA19-9 level and NLR at baseline were statistically significantly associated with worse OS. There appeared to be a treatment 
effect for OS favoring nab-paclitaxel plus gemcitabine over gemcitabine alone in poor-prognosis subgroups defined by these 
factors (HR = 0.612, P < .001 for CA19-9 level ≥ median and HR = 0.81, P = .079 for NLR > 5).
Conclusions: These data confirm and extend the primary report of OS, supporting the superior efficacy of nab-paclitaxel 
plus gemcitabine over gemcitabine alone. Subgroup analyses support the relevance of CA 19-9 and NLR as prognostic 
markers in metastatic pancreatic cancer.
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Pancreatic cancer is one of the deadliest tumor types, account-
ing for approximately 7% of all cancer deaths in the United 
States (1). Among all cancer types, pancreatic cancer ranks 11th 
in incidence but fourth in mortality (1). Gemcitabine monother-
apy became a standard first-line treatment option for metastatic 
pancreatic cancer after it demonstrated superior clinical benefit 
over 5-fluorouracil (2–4). Median overall survival (OS) for patients 
who received gemcitabine monotherapy for advanced pancre-
atic cancer in key trials has ranged from 5.7 to 6.8 months (2,5,6). 
Experimental treatment arms have failed to statistically signifi-
cantly improve OS over gemcitabine in numerous phase III trials 
(7–13). In fact, until recently, only two trials had demonstrated 
statistically significant improvements in OS over gemcitabine 
for patients with this disease: a phase III study that showed a 
modest benefit for patients receiving gemcitabine plus erlotinib 
(median = 6.24 vs 5.91 months, hazard ratio [HR] = 0.82, P = .038, 
12-month OS rates of 23% vs 17%) and a phase II/III trial that 
found a statistically significant OS benefit for leucovorin, 5-fluo-
rouracil, irinotecan, and oxaliplatin (FOLFIRINOX, median = 11.1 
vs 6.8 months, HR = 0.57, P < .001), although FOLFIRINOX was 
also associated with a marked potential for toxicity (5,6).
nab-Paclitaxel ([Abraxane], Celgene Corporation, Summit, NJ) 
is an albumin-based formulation of paclitaxel that has demon-
strated clinical benefit over solvent-based paclitaxel in patients 
with metastatic breast cancer (14) and non–small cell lung can-
cer (15). A 2011 report revealed encouraging initial findings for 
patients with metastatic pancreatic adenocarcinoma treated 
at the maximum tolerated dose of nab-paclitaxel plus gem-
citabine in a phase I/II trial: a median OS of 12.2  months, an 
overall response rate by Response Evaluation Criteria In Solid 
Tumors (RECIST) of 48%, and a median progression-free survival 
of 7.9 months (16).
These results led to an international phase III trial (MPACT, 
ClinicalTrials.gov, trial number NCT00844649) in which 861 
patients with metastatic pancreatic cancer were randomly 
assigned to receive nab-paclitaxel plus gemcitabine at the rec-
ommended doses from the phase I/II study (nab-paclitaxel 
125 mg/m2 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15 of 
each 28-day cycle) or gemcitabine alone (17). Treatment with nab-
paclitaxel plus gemcitabine demonstrated statistically signifi-
cant improvements across all endpoints vs gemcitabine alone, 
including OS (primary endpoint, median  =  8.5 vs 6.7  months, 
HR = 0.72, 95% confidence interval [CI] = 0.62 to 0.83, P < .001), 
progression-free survival (median = 5.5 vs 3.7 months, HR = 0.69, 
95% CI  =  0.58 to 0.82, P < .001), and independently reviewed 
overall response rate (23% vs 7%, response rate ratio = 3.19, 95% 
CI = 2.18 to 4.66, P < .001). The most common grade 3 or higher 
adverse events with nab-paclitaxel plus gemcitabine were neu-
tropenia, leukopenia, fatigue, and peripheral neuropathy.
Examination of prognostic markers at baseline may aid in 
designing more effective treatment plans for patients with meta-
static pancreatic cancer (18). Carbohydrate antigen 19-9 (CA19-9) 
is a prognostic marker that has proven useful 18-21). However, not 
all patients secrete Lewis antigens such as CA19-9, and only 80% 
to 85% of patients can possibly demonstrate an elevated CA19-9 
level (19,21). Furthermore, an elevated CA19-9 level could lead to a 
false-positive cancer diagnosis, suggesting that additional mark-
ers are needed. Retrospective studies suggest that neutrophil-
to-lymphocyte ratio (NLR), a marker of systemic inflammatory 
response, may provide valuable prognostic information in many 
malignancies, including pancreatic cancer (22–27).
The initial publication of the MPACT trial reported an OS anal-
ysis in which 80% of patients had died (17). This report describes 
an updated analysis of OS from MPACT with an extended data 
cutoff (eight months longer) at the time the trial was closed. At 
that time, 90% of patients in the intent-to-treat (ITT) population 
had died. Additional analyses include the prognostic impacts of 
baseline CA19-9 levels and NLR on OS and evaluations of treat-
ment effect in patient subgroups defined by these factors.
Methods
The study design and patient characteristics have been 
described previously (17). Key parameters are described below. 
The independent ethics committee at each participating institu-
tion approved the study. All patients provided written informed 
consent before the initiation of the study.
Patients
A total of 861 adults (≥18  years of age) with a Karnofsky per-
formance status (KPS) score of 70 or higher and histologically 
or cytologically confirmed metastatic adenocarcinoma of the 
pancreas were enrolled. Disease was required to be measurable 
by RECIST version 1.0 (28). Additional eligibility criteria included 
adequate hepatic, hematologic, and renal function (including a 
bilirubin level ≤ the upper limit of the normal range, an absolute 
neutrophil count ≥ 1.5 × 109/L, and a hemoglobin level ≥ 9 g/dL). 
Treatment with fluorouracil or gemcitabine as a radiation sen-
sitizer in the adjuvant setting was allowed if given at least six 
months prior to random assignment.
Previous chemotherapy for metastatic disease was an exclu-
sion criterion for this study. Patients with islet cell neoplasms 
or locally advanced adenocarcinoma were also excluded, as 
were patients who had received cytotoxic doses of any systemic 
chemotherapy, including gemcitabine, in the adjuvant setting.
Study Design and Treatment
This was an international, multicenter, open-label, phase III 
study conducted at 151 sites. Patients were randomly assigned 
in a one to one ratio to receive a 30- to 40-minute intravenous 
infusion of nab-paclitaxel 125 mg/m2, followed by an infusion of 
gemcitabine 1000 mg/m2 on days 1, 8, 15, 29, 36, and 43, or gem-
citabine alone 1000 mg/m2 weekly for seven of eight weeks (cycle 
1). Patients received treatment on days 1, 8, and 15 every four 
weeks in subsequent cycles. Patient random assignment was 
stratified by geographic region, performance status, and liver 
metastases. Treatment continued until either disease progres-
sion or unacceptable toxicity.
Assessments
Tumor response was evaluated every eight weeks by spiral com-
puted tomography or magnetic resonance imaging. Scans were 
evaluated by investigators and by an independent radiological 
evaluation using RECIST version 1.0. CA19-9 level was assessed at 
baseline and every eight weeks thereafter. NLR was evaluated at 
baseline; subgroup analyses were based on a cutoff ratio of five, 
per a previous publication in advanced pancreatic cancer (22).
Investigators monitored treatment-related adverse events 
and serious adverse events, weekly central laboratory test-
ing, and the rates of dose reductions, dose interruptions, and 
premature discontinuations of the study drug. Treatment-
related adverse events were graded in accordance with the 
National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0 (http://ctep.cancer.gov/proto-
colDevelopment/electronic_applications/docs/ctcaev3.pdf) 
and coded to correspond with the preferred terms in the 
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Medical Dictionary for Regulatory Activities version 15.0. The 
safety data reported here are updated from the original pub-
lication (17).
Statistical Analysis
All efficacy analyses were performed on the ITT population, 
which was composed of all enrolled patients. The primary 
efficacy endpoint was OS, which was analyzed for all ran-
domly assigned patients by the Kaplan-Meier method. Per 
the study protocol, the treatment effect on OS was assessed 
for statistical significance by a log-rank test stratified by the 
prespecified random assignment stratification criteria of geo-
graphic region (North America vs other), baseline KPS (70 to 
80 vs 90 to 100), and presence of liver metastases (yes vs no). 
Survival data for patients who were lost to follow-up were 
censored at the last date at which they were known to be 
alive. A  patient population of 842 patients with 608 events 
allowed 90% power to detect a hazard ratio of 0.769 at a two-
sided α level of 0.049 for death with nab-paclitaxel plus gem-
citabine vs gemcitabine alone. The data cutoff for the original 
OS analysis was September 17, 2012. The data cutoff for this 
updated analysis was May 9, 2013, which corresponded to 
the date the trial was closed following complete analysis of 
the post-study 120-day safety evaluation conducted as part 
of the standard regulatory process. The secondary endpoints 
were progression-free survival and overall response rate (not 
updated in this analysis because they were not likely to have 
changed with extended follow-up).
A multivariable survival analysis for OS was carried out using 
a Cox proportional hazards model that included the complete set 
of prespecified baseline factors: treatment group, age, sex, KPS, 
geographic region, primary tumor location within the pancreas, 
presence of biliary stent, previous Whipple procedure, presence 
of liver metastasis, presence of lung metastasis, peritoneal car-
cinomatosis, stage at diagnosis, number of metastatic sites, and 
CA19-9 level. Baseline NLR was added to the model for a post hoc 
exploratory analysis. The OS analyses reported in this study did 
not require tests for homogeneity because they were based on 
proportional hazard models rather than linear models. Factors 
with a P value under .10 were considered significant and allowed 
to remain in the model per the study protocol. Baseline CA19-9 
level was analyzed as a continuous variable, and the hazard ratio 
was based on EXP (CA19-9 coefficient), where EXP is the exponen-
tial function. To address the statistical issue of multiple compari-
sons, we performed a Bonferroni correction on the multivariable 
model of OS, using α/k, in which α represents the statistical level 
of significance used to test the variables in the mode (α =  .05) 
and k is the total number of independent variables tested (k = 6).
A descriptive evaluation of baseline characteristics based on 
survival durations was performed within each treatment arm. 
This evaluation was qualitative and not subject to statistical 
analysis.
All statistical tests were two-sided and performed using 
Statistical Analysis Software (SAS) version 9.2. All P values were 
derived from Wald χ2 tests, except for the comparison of OS 
(described previously).
Results
A total of 431 patients were assigned to the nab-paclitaxel plus 
gemcitabine arm, and 430 were assigned to the gemcitabine-
alone arm (ITT population) (Figure  1). All demographic and 
clinical characteristics at baseline were well balanced between 
the two groups (Table 1). Most patients (84%) had metastasis to 
the liver, and more than 50% of patients had baseline CA19-9 
levels greater than or equal to 59 × the upper limit of normal. 
CA19-9 level at baseline was not produced by 13% of patients.
Overall Survival in the ITT Population
The median follow-up for this updated survival analysis 
was 13.9 months. The data were based on 774 deaths (90% of 
patients), including 380 in the nab-paclitaxel plus gemcitabine 
group (88%) and 394 in the gemcitabine-alone group (92%). The 
median OS for patients who received nab-paclitaxel plus gem-
citabine (8.7 months, 95% CI = 7.89 to 9.69) was statistically sig-
nificantly longer than for those who received gemcitabine alone 
(6.6 months, 95% CI = 6.01 to 7.20, HR = 0.72, 95% CI = 0.62 to 0.83, 
P < .001) (Figure 2A). The time point at which 25% of the patients 
were alive was later for nab-paclitaxel plus gemcitabine than 
for gemcitabine alone (14.8 months [95% CI = 13.93 to 15.64] vs 
11.1  months [95% CI  =  10.12 to 12.39]). A  previous sensitivity 
analysis in which data were censored at the time of secondary 
therapy confirmed the findings of the OS analysis (17). Extended 
follow-up also identified patients who survived longer than 
24  months in the nab-paclitaxel plus gemcitabine treatment 
arm (Table  2), including 4% of patients who survived at least 
36 months and 3% of patients who survived at least 42 months. 
No patients survived for 36 months in the gemcitabine-alone 
treatment group. The treatment effect favoring nab-paclitaxel 
plus gemcitabine over gemcitabine alone remained statistically 
significant across most patient subgroups (Figure 2B).
A Cox multivariable analysis model of the 643 patients for 
whom data on all factors tested were available found that treat-
ment group, presence of liver metastases, KPS, age, and baseline 
Figure  1. Updated Consolidated Standards of Reporting Trials diagram as of 
May 9, 2013. *One patient was randomly assigned to gemcitabine (Gem) but was 
treated with nab-paclitaxel + Gem. In the intent-to-treat analysis, this patient 
was analyzed as randomly assigned. In all analyses of the treated population, 
the patient was analyzed as treated. CONSORT  =  Consolidated Standards of 
Reporting Trials; Gem  =  gemcitabine; ITT  =  intent-to-treat; nab-P  =  nab-pacli-
taxel; OS = overall survival.
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NLR were all independent predictors of survival (Table 3); how-
ever, the number of metastatic sites did not reach statistical sig-
nificance (P = .105) in this model. The baseline characteristics of 
the patients included in the multivariable analysis were similar 
to those of the ITT population (Supplementary Table 1, available 
online). In a Bonferroni-corrected model, the cutoff for statisti-
cal significance was 0.008, and the factors that remained signifi-
cant were treatment (HR = 0.68, 95% CI = 0.57 to 0.80, P < .001), 
liver metastasis (HR = 1.65, 95% CI = 1.28 to 2.12, P < .001), KPS 
(HR = 1.47, 95% CI = 1.24 to 1.74, P < .001), and NLR (HR = 0.57, 95% 
CI = 0.48 to 0.68, P < .001).
In a further effort to understand which baseline charac-
teristics may have influenced survival, patients within each 
treatment arm were divided into subgroups based on survival 
duration, and the baseline characteristics of each survival 
subgroup were evaluated (Table  4). Baseline characteristics of 
long-term (≥two-year) survivors were similar between the two 
groups, with the exception of sex (48% male in the nab-pacli-
taxel plus gemcitabine group vs 64% male in the gemcitabine-
alone group) and baseline CA19-9 levels. A higher proportion of 
patients with elevated baseline CA19-9 levels (≥ 59 × the upper 
limit of normal) were alive for two years or longer with nab-
paclitaxel plus gemcitabine treatment than with gemcitabine 
alone (55% vs 15%).
Subgroup Analyses
The median baseline CA19-9 level for all patients was 2470 U/mL 
(range = 0.3-12 207 654). Among patients with a baseline CA19-9 
level greater than or equal to the median, OS was statistically 
significantly longer for those who received nab-paclitaxel plus 
gemcitabine than for those who received gemcitabine alone 
(HR  =  0.612, 95% CI  =  0.49 to 0.76, P < .001) (Figure  3). Among 
patients with a baseline CA19-9 level less than the median, 
there was a trend toward a treatment effect on OS favoring nab-
paclitaxel plus gemcitabine (HR = 0.833, 95% CI = 0.67 to 1.04, 
P = .113). Notably, the OS for patients treated with nab-paclitaxel 
plus gemcitabine was similar regardless of whether baseline 
CA19-9 levels were less than the median or greater than or 
equal to the median (HR = 0.983, 95% CI = 0.79 to 1.23, P = .470). 
However, in the gemcitabine-alone arm, OS was statistically 
significantly longer in patients with baseline CA19-9 levels less 
than the median compared with patients whose baseline CA19-9 
levels were greater than or equal to the median (HR = 0.773, 95% 
CI = 0.62 to 0.97, P = .001).
A pooled treatment arm analysis of the updated OS data 
revealed that patients with an NLR of less than or equal to five 
(n = 543) had a statistically significantly better OS compared with 
patients whose NLR was greater than five (n = 309, median = 9.1 
vs 5.0 months, HR = 1.839, P < .001) (Figure 4). nab-Paclitaxel plus 
gemcitabine (n  =  266) resulted in a statistically significantly 
longer OS vs gemcitabine alone (n  =  277) in patients with an 
NLR of less than or equal to five (median = 10.9 vs 7.9 months, 
HR  =  0.67, P < .001). A  similar trend favoring nab-paclitaxel 
plus gemcitabine (n = 160) vs gemcitabine alone (n = 149) was 
observed in the NLR over five group, although this difference did 
not reach statistical significance (median = 5.6 vs 4.3 months, 
HR = 0.81, P = .079).
Consistent with the results for the overall population, a treat-
ment benefit favoring nab-paclitaxel plus gemcitabine over gem-
citabine alone was noted in subgroups based on performance 
status (P < .001 for KPS 70-80 and P = .005 for KPS 90-100) and the 
presence (P < .001) or absence (P = .111) of liver metastases. Within 
each treatment arm, these factors remained prognostic of survival. 
Patients with a KPS of 90 to 100 had a better OS than patients with 
a KPS of 70 to 80 in both the nab-paclitaxel plus gemcitabine arm 
(9.7 vs 7.6 months, HR = 0.76, P = .009) and the gemcitabine-alone 
arm (7.9 vs 4.3 months, HR = 0.57, P < .001). Similarly, the absence 
of liver metastases was associated with a better OS than the pres-
ence of liver metastases in the nab-paclitaxel plus gemcitabine 
arm (11.1 vs 8.3 months, HR = 0.58, P = .001) and the gemcitabine-
alone arm (10.2 vs 5.9 months, HR = 0.58, P < .001).
Table 1. Baseline patient characteristics (17)
Variable
nab-P + Gem 
(n = 431)
Gem 
(n = 430)
All patients 
(n = 861)
Age
Median years (range), y 62 (27-86) 63 (32-88) 63 (27-88)
< 65 y, % 59 56 58
≥ 65 y, % 41 44 42
Sex, %
Male 57 60 58
Race, %
Asian 2 2 2
Black 4 4 4
White 88 87 87
Hispanic 6 6 6
Other 1 1 1
KPS, %
100 16 16 16
90 42 46 44
80 35 30 32
70 7 8 7
60 <1* 0 <1
Pancreatic primary tumor 
location, %
Head 44 42 43
Body 31 32 31
Tail 24 26 25
Unknown 1 1 1
Current site(s) of  
metastasis, %
Liver 85 84 84
Lung 35 43 39
Peritoneum 4 2 3
No. of metastatic sites, %
1 8 5 6
2 47 48 47
3 32 33 32
> 3 14 15 14
CA19-9 level†
Median, U/mL 2294 2759 2470
Normal, % 16 15 15
ULN to < 59 × ULN, % 32 32 32
≥ 59 × ULN, % 52 53 52
Previous therapy, %
Radiation 4 3 3
Chemotherapy 5 3 4
Whipple procedure 7 7 7
Biliary stent 19 16 17
* Two patients had a Karnofsky performance status (KPS) of 70 at screening but 
a KPS of 60 at baseline on day 1 of cycle 1. CA19-9 = carbohydrate antigen 19-9; 
Gem = gemcitabine; KPS = Karnofsky performance status; nab-P = nab-paclitaxel; 
ULN = upper limit of normal.
† Not all patients have Lewis antigens and thus cannot secrete CA19-9. The 
evaluable n for CA19-9 was 379 patients in the nab-P + Gem group and 371 
patients in the Gem-alone group.
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Safety
The most common grade 3 or higher adverse events were pre-
viously reported (17). Briefly, nab-paclitaxel plus gemcitabine 
appeared to increase the rates of any-grade neutropenia, leu-
kopenia, fatigue, peripheral neuropathy, and diarrhea (Table 5). 
The addition of nab-paclitaxel did not appear to substantially 
increase the rates of any-grade anemia or thrombocytopenia. 
The number of patients who experienced at least one grade 3 
or higher treatment-related, treatment-emergent adverse event 
was 326 (77%) in the nab-paclitaxel plus gemcitabine arm and 205 
(51%) in the gemcitabine-alone arm. The frequency and severity 
of adverse events was not influenced by baseline performance 
status, as demonstrated by the similar rates of adverse events 
between patients with KPS 70 to 80 and KPS 90 to 100 (Table 5). 
Grade 3 peripheral neuropathy occurred in 71 patients (17%) in 
the nab-paclitaxel plus gemcitabine arm. Of these 71 patients, 31 
(44%) experienced an improvement to grade 1 or less after dose 
delay. The median time to improvement to grade 1 or less neu-
ropathy was 29 days, and 44% of patients were able to resume 
treatment with nab-paclitaxel.
Discussion
This updated analysis of the phase III MPACT trial confirmed the 
treatment effect in favor of nab-paclitaxel plus gemcitabine vs 
gemcitabine alone for OS (more than a two-month difference at 
the median, P < .001), including at the tail of the survival curve. 
The extended data cutoff allowed an OS analysis of mature data 
from 90% of the patients in the study. This led to the identifica-
tion of long-term (≥three-year) survivors in the nab-paclitaxel 
plus gemcitabine arm (4%) and an evaluation of baseline char-
acteristics shared by long-term survivors vs the ITT population.
In a new multivariable analysis, visceral metastases and KPS 
were found to be statistically significant independent predictors 
A
Events/n Median, mo (95% CI)
75th 
percentile
380/431 8.7 (7.89 to 9.69) 14.8
394/430 6.6 (6.01 to 7.20) 11.1
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HR = 0.72
95% CI (0.62 to 0.83)
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Figure 2. Updated overall survival (intent-to-treat population). A) Kaplan-Meier overall survival (OS) curve. P value from stratified log-rank test. B) Forest plot of the 
hazard ratios for OS in patient subgroups. P values from Wald χ2 tests. All statistical tests were two-sided. CI = confidence interval; Gem = gemcitabine, HR = hazard 
ratio; KPS = Karnofsky performance status; nab-P = nab-paclitaxel; OS = overall survival; ULN = upper limit of normal.
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of survival, as was age (Table 3). In this unadjusted multivariable 
model of the extended analysis, NLR at baseline was also a signifi-
cant predictor of OS (P ≤ .001) (Table 3). Adjustment by Bonferroni 
correction eliminated age as an independent predictor of survival.
This follow-up study also yielded interesting findings regard-
ing subgroup treatment effects based on CA19-9 levels and NLR, 
two known markers of prognosis. CA19-9 level is elevated in 
approximately 60% to 80% of patients with advanced pancreatic 
cancer, and it has been used as an aid in assessing the extent 
of disease and as a marker of tumor response (18,29). Studies 
have indicated that higher baseline CA19-9 levels are generally 
associated with poorer clinical outcomes, including one report 
specific to patients who received gemcitabine therapy (18–20). 
Patients treated with nab-paclitaxel plus gemcitabine demon-
strated similar OS regardless of whether baseline CA19-9 levels 
were less than the median or greater than or equal to the median 
(Figure 3), whereas in the gemcitabine-alone arm, OS was statis-
tically significantly longer for patients with baseline CA19-9 lev-
els less than the median vs greater than or equal to the median 
(P = .001) (Figure 3). In addition, among patients with a baseline 
Table 2. Overall survival rates: update as of May 9, 2013*
Time point
Survival rate, %
nab-P + Gem (n = 431) Gem (n = 430)
6 months 66 55
12 months 35 22
24 months 10 5
36 months 4 0
40 months 3 0
42 months 3 0
*Gem = gemcitabine; nab-P = nab-paclitaxel.
Table 3. Multivariable analysis of overall survival based on updated 
data as of May 9, 2013*
Covariable
Updated analysis
HR (95% CI) P†
Treatment  
nab-P + Gem vs Gem
0.68 (0.57 to 0.80) <.001
Presence of liver metastases  
Yes vs no
1.65 (1.28 to 2.12) <.001
KPS  
70-80 vs 90-100
1.47 (1.24 to 1.74) <.001
NLR  
≤ 5 vs > 5
0.57 (0.48 to 0.68) <.001
Age  
< 65 vs ≥ 65 years
0.81 (0.69 to 0.96) .016
Geographic region  
Eastern Europe vs North 
America
1.19 (0.99 to 1.43) .063
* Gem = gemcitabine, HR = hazard ratio; KPS = Karnofsky performance status; 
nab-P = nab-paclitaxel; NLR = neutrophil-to-lymphocyte ratio.
† P values from two-sided Wald χ2 tests.
Table 4. Baseline characteristics in subgroups divided by overall survival duration*
Variable
All patients (17) 1- to 2-year survivors >2-year survivors
nab-P + Gem 
(n = 431) Gem (n = 430)
nab-P + Gem 
(n = 119) Gem (n = 76)
nab-P + Gem 
(n = 25) Gem (n = 14)
Median age, y 62 63 62 63 61 64
(range) (27-86) (32-88) (27-80) (41-85) (46-78) (50-83)
 ≥ 65 years, % 41 44 36 47 28 36
Male, % 57 60 55 49 48 64
Race, %
 Asian 2 2 1 0 8 14
 Black 4 4 3 3 8 0
 White 88 87 89 89 80 79
 Hispanic 6 6 5 8 4 7
 Other 1 1 2 0 0 0
Region, %
 Australia 14 14 13 11 20 14
 Eastern Europe 15 14 11 11 8 21
 North America 62 63 66 67 72 64
 Western Europe 9 9 9 12 0 0
KPS, %
 100 16 16 20 26 32 50
 90 42 46 39 53 48 36
 80 35 30 39 17 20 14
 70 7 8 2 4 0 0
 60 <1 0 0 0 0 0
Liver metastases, % 85 84 84 74 56 57
CA19-9 level, %
 Normal 16 15 14 15 15 38
 ULN to < 59 × ULN 32 32 34 42 30 46
 ≥ 59 × ULN 52 53 51 43 55 15
 ≤ Median 51 49 51 60 45 85
 > Median 49 51 49 40 55 15
*CA19-9 = carbohydrate antigen 19-9; Gem = gemcitabine; KPS = Karnofsky performance status; nab-P = nab-paclitaxel; ULN = upper limit of normal.
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CA19-9 level greater than or equal to the median, OS was sta-
tistically significantly longer for those who received nab-pacli-
taxel plus gemcitabine vs those who received gemcitabine alone 
(P < .001) (Figure 3). These results suggest that nab-paclitaxel was 
able to reduce or overcome the effect of baseline CA19-9 level as 
a prognostic factor, whereas treatment with gemcitabine alone 
was not. This may reflect an improved response rate, reduc-
ing the impact of a higher tumor burden, or it may reflect that 
the combination acts on metabolic pathways not amenable to 
blockade by gemcitabine alone (30).
Although it has not yet been as thoroughly evaluated in 
pancreatic cancer, NLR—a marker of systemic inflammatory 
response—is an important prognostic factor for a number of 
malignancies, including colorectal cancer and non–small cell 
lung cancer (31–33). This inflammatory response appears to 
promote the microenvironment to facilitate tumor progression 
and metastasis (34). Recently, elevated baseline NLR was shown 
to predict shorter OS in a retrospective analysis of patients 
who were treated with gemcitabine-based chemotherapy for 
advanced pancreatic cancer (median = 2.4 months for patients 
with an NLR > 5 vs 7.7  months for patients with an NLR ≤ 5, 
HR = 5.77, P < .001) (22). However, similar analyses in prospective 
clinical trials have been lacking. The multivariable analysis in 
this follow-up report confirmed the prognostic significance of 
NLR, and the median OS for patients with an NLR of less than or 
equal to vs greater than five was 9.1 vs 5.0 months, respectively. 
Among patients with an NLR greater than five, the hazard ratio 
of 0.81 and P value of 0.079 suggest a trend toward a treatment 
effect favoring nab-paclitaxel plus gemcitabine. The observed 
association of neutrophilia with angiogenesis suggests that this 
patient subset may benefit from the addition of antiangiogenic 
therapy, despite its lack of benefit in unstratified trials (8,23,35).
The utility of this regimen may be further refined once the 
results of additional potentially predictive molecular studies 
Figure 3. Overall survival by treatment and baseline CA19-9 level. Kaplan-Meier survival curve of subgroups divided by treatment arm and baseline CA19-9 level (less 
than or greater than or equal to the median). Gem = gemcitabine; nab-P = nab-paclitaxel; OS = overall survival.
Figure 4. Overall survival by treatment and baseline neutrophil-to-lymphocyte ratio (NLR). Kaplan-Meier survival curve of subgroups divided by treatment arm and 
baseline NLR (less than or equal to or greater than five). Gem = gemcitabine; nab-P = nab-paclitaxel; OS = overall survival.
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are completed. Initial data on secreted protein acidic and rich 
in cysteine (SPARC) expression in the phase I/II trial suggested 
enhanced efficacy in tumors that expressed higher vs lower 
levels of SPARC (17). SPARC analyses from the MPACT trial are 
currently ongoing and will be the subject of future publications.
This study is likely to be broadly representative of the popula-
tion of patients with metastatic disease. Limitations of our study 
include the lack of a quality-of-life analysis and the addition of 
post hoc analyses and multiple comparisons that were not pre-
specified in the study’s statistical plan. Like all post hoc subgroup 
analyses, the comparisons of OS in subsets defined by NLR and 
CA 19-9 were susceptible to the possibility of spurious findings.
In conclusion, these updated results confirm and expand on 
the longer-term benefits of the previously reported treatment 
effect favoring nab-paclitaxel plus gemcitabine for OS. They 
further support the use of this combination therapy as a new 
standard option for patients with advanced pancreatic cancer, 
including those with higher-risk baseline features, such as those 
with a KPS of 70 to 80 in whom no increases in grade 3 or higher 
adverse events were observed. In addition, nab-paclitaxel plus 
gemcitabine may be an excellent comparator for future studies. 
Finally, nab-paclitaxel plus gemcitabine may serve as a backbone 
on which to add other therapies for patients with this disease.
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Table 5. Safety
Select adverse events
nab-P + Gem Gem
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Any grade Grade 1 Grade 2 Grade 3 Grade 4
Hematologic, n (%)
 All treated n = 405* n = 388
 KPS 90-100 n = 241 n = 241
 KPS 70-80 n = 164† n = 146
Neutropenia
 All treated 297 (73) 43 (11) 101 (25) 107 (26) 46 (11) 225 (58) 35 (9) 86 (22) 83 (21) 21 (5)
 KPS 90-100 185 (77) 22 (9) 65 (27) 67 (28) 31 (13) 156 (65) 20 (8) 60 (25) 60 (25) 16 (7)
 KPS 70-80 112 (68) 21 (13) 36 (22) 40 (24) 15 (9) 68 (47) 15 (10) 25 (17) 23 (16) 5 (3)
Leukopenia
 All treated 357 (88) 100 (25) 130 (32) 116 (29) 11 (3) 298 (77) 116 (30) 119 (31) 59 (15) 4 (1)
 KPS 90-100 220 (91) 56 (23) 83 (34) 72 (30) 9 (4) 200 (83) 72 (30) 86 (36) 39 (16) 3 (1)
 KPS 70-80 137 (84) 44 (27) 47 (29) 44 (27) 2 (1) 97 (66) 44 (30) 32 (22) 20 (14) 1 (1)
Thrombocytopenia
 All treated 302 (75) 169 (42) 81 (20) 43 (11) 9 (2) 272 (70) 162 (42) 73 (19) 29 (7) 8 (2)
 KPS 90-100 191 (79) 105 (44) 50 (21) 28 (12) 8 (3) 179 (74) 108 (45) 49 (20) 19 (8) 3 (1)
 KPS 70-80 111 (68) 64 (39) 31 (19) 15 (9) 1 (1) 93 (64) 54 (37) 24 (16) 10 (7) 5 (3)
Anemia
 All treated 393 (97) 104 (26) 233 (58) 52 (13) 4 (1) 374 (96) 136 (35) 189 (49) 43 (11) 6 (2)
 KPS 90-100 236 (98) 69 (29) 139 (58) 25 (10) 3 (1) 235 (98) 93 (39) 109 (45) 30 (12) 3 (1)
 KPS 70 - 80 157 (96) 35 (21) 94 (57) 27 (16) 1 (1) 139 (95) 43 (29) 80 (55) 13 (9) 3 (2)
Receipt of growth factors, n/N (%)
 ITT 110/431 (26) 63/430 (15)
 KPS 90-100 72/248 (29) 43/268 (16)
 KPS 70-80 38/179 (21) 20/161 (12)
Nonhematologic, n (%)
 All treated n = 421 n = 402c
 KPS 90-100 n = 246 n = 248
 KPS 70-80 n = 174 n = 153
Fatigue
 All treated 228 (54) 51 (12) 104 (25) 72 (17) 1 (<1) 147 (37) 53 (13) 67 (17) 26 (6) 1 (<1)
 KPS 90-100 139 (57) 34 (14) 72 (29) 33 (13) 0 94 (38) 42 (17) 38 (15) 14 (6) 0
 KPS 70-80 89 (51) 17 (10) 32 (18) 39 (22) 1 (1) 53 (35) 11 (7) 29 (19) 12 (8) 1 (1)
Peripheral neuropathy‡
 All treated 221 (52) 94 (22) 56 (13) 71 (17) 0 21 (5) 18 (4) 2 (<1) 1 (<1) 0
 KPS 90-100 142 (58) 58 (24) 36 (15) 48 (20) 0 13 (5) 12 (5) 1 (<1) 0 0
 KPS 70-80 79 (45) 36 (21) 20 (11) 23 (13) 0 8 (5) 6 (4) 1 (1) 1 (1) 0
Diarrhea
 All treated 157 (37) 82 (19) 51 (12) 24 (6) 0 53 (13) 34 (8) 16 (4) 3 (1) 0
 KPS 90-100 99 (40) 54 (22) 30 (12) 15 (6) 0 32 (13) 19 (8) 10 (4) 3 (1) 0
 KPS 70-80 58 (33) 28 (16) 21 (12) 9 (5) 0 21 (14) 15 (10) 6 (4) 0 0
* n = 404 for thrombocytopenia in all treated patients. Gem = gemcitabine; ITT = intent-to-treat; KPS = Karnofsky performance status; nab-P = nab-paclitaxel.
† n = 163 for thrombocytopenia for patients with a KPS of 70 to 80.
‡ Peripheral neuropathy was reported on the basis of preferred terms defined by the standardized queries in the Medical Dictionary for Regulatory Activities version 15.0.
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